home-hero.jpg

Outsourcing for the pharmaceutical industry

Welcome to the Dishman Carbogen Amcis Ltd website. Our organization has embarked upon a new and exciting era; therefore, our online presence has undergone a complete refresh and total restructuring.

Please feel free to contact us with any queries or browse our newly refurbished corporate portal.

Our Mission

The mission of Dishman Carbogen Amcis Ltd and its fundamental purpose is to offer support and assistance to people across the world suffering from illness and disease, striving to ensure that this is completed efficiently, comprehensively, and effectively.

Latest News

  • Sanjeev Jain

    Sanjeev Jain
    Vice President – IT

    +91 7202000869
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Read more

  • Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    News

    Pascal Villemagne appointed new CARBOGEN AMCIS Chief Executive Officer (CEO)

    BUBENDORF, Switzerland (March 31, 2022) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announces that Pascal Villemagne has been named Chief Executive Officer, effective first of April

    In his new role, Pascal Villemagne will be leading CARBOGEN AMCIS and its nine sites around the world. He will report to Arpit Vyas, Global Managing Director of Dishman Carbogen Amcis Ltd., CARBOGEN AMCIS’ parent company. Villemagne, who has served as Vice...

    Read more

  • Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    News

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on Clinical Research Study that reveals positive response in vitamin D deficiency/insufficiency in patients with COVID-19

    Ahmedabad, India (December 9th, 2021) — Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new Clinical Research Study which shows that oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and that it resulted in improved immune function by increasing...

    Read more

  • Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency

    News

    Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine on study that uncovers treatment for vitamin D deficiency

    Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Ltd, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly-owned...

    Read more

  • CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    News

    CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    BUBENDORF, Switzerland (August 17, 2020) — Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France. 

    CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers. The new facilities, located in Switzerland and France, will...

    Read more

  • Dishman Carbogen Amcis Ltd Statement on COVID-19

    News

    Dishman Carbogen Amcis Ltd Statement on COVID-19

    Dear Customers and Partners,

    We at Dishman Carbogen Amcis group of companies are taking the risks associated with COVID-19 very seriously, and have already implemented a set of measures aimed at limiting any risk to our employees, customers and patients. We have already established a dedicated working team who monitor the COVID-19 outbreak and all processes have been analyzed with regards to risks. This allows us to have all our operations running smoothly and we currently do not have an impact on our operations.

    We are facing a unique situation in several of the countries where...

    Read more

    Upcoming events

      QUARTERNARY AMMONIUM SALTS EXPLAINED

      Dishman Carbogen Amcis Ltd. has rich expertise in Quaternary Ammonium Salts (Quats) with a robust and established portfolio. But do you know about their many benefits and applications? Watch the video to learn more about the Quats and discover how they could benefit you.

      Key Figures

      COVID-19 UPDATE

      As part of our commitment to continue the long fight against COVID-19, we have doubled the manufacturing capacity of some of our disinfectant API production facilities. Since March 2020, we have manufactured and globally exported more than 300 metric tons of disinfectant APIs.

      10 sites
      in India, Switzerland, UK, France, Netherlands & China
      30 years
      of experience in clinical API development
      100 metric tons
      scale manufacturing for API production
      1150 m3
      of capacity for API production
      300 metric tons
      of disinfectant APIs manufactured and exported to fight COVID-19 since 03/2020

      CONTACT US TODAY OR DOWNLOAD
      OUR COMPANY PROFILE BROCHURE
      FOR FURTHER INFORMATION

      SUBSCRIBE TO OUR MAILING LIST FOR THE LATEST NEWS UPDATES